Inozyme Pharma Inc at Cowen Health Care Conference Transcript
Welcome back to the 43rd Annual TD Health Care Conference. Marc Frahm from the biotech team, joined by my colleagues, [Peten Bundestag], [Cullen Scott] over here as well as we've got four companies on this panel, that has focus on neuromuscular and bone orphan diseases. So, we've got from Applied Therapeutics, Shoshana Shendelman, Founder, and CEO; from Entrada Therapeutics, Nathan Dowden, the COO, right? And then from Inozyme, Axel Bolte, CEO; Rallybio, Martin Mackay, the CEO.
The plan is to start off with some general questions that are [charismatic] across mostly just orphan disease, more generally, than even just neuromuscular and bone. And then eventually move into more company-specific questions. We're also more than open to taking questions from the audience. You can submit those by submitting to [[email protected]] And it will come up here, and we will try to put those into the list as well.
Questions & Answers
Maybe to start off with, several companies on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |